Core Insights - Aethlon Medical, Inc. reported financial results for its fiscal second quarter ended September 30, 2025, highlighting clinical progress and cost reductions [1][12][13]. Clinical and Corporate Update - The company is advancing its clinical initiatives, particularly in cancer treatment, and has resolved Nasdaq compliance matters, maintaining its listing [2][16]. - Recruitment for the second cohort of the Australian oncology trial of the Hemopurifier® has begun, allowing patients to receive combination therapies with Pembrolizumab or Nivolumab [3][9]. - The primary endpoint of the study is safety, with plans to enroll approximately 9 to 18 participants [9]. Scientific Developments - Analysis of extracellular vesicles (EVs) from patients in the first cohort showed decreases in large EVs after Hemopurifier treatment, which are implicated in cancer progression [4]. - Improvements in laboratory ratios associated with immunotherapy responses were observed in at least two participants following treatment [6]. - Ongoing collaboration with UCSF focuses on Long COVID research, with a manuscript in preparation for peer-reviewed publication [10]. Financial Performance - Operating expenses decreased by 48% to approximately $1.5 million for the quarter, down from $2.9 million in the same period in 2024 [12][14]. - The operating loss for the quarter decreased to $1.5 million compared to $2.8 million in the prior-year period [15]. - As of September 30, 2025, Aethlon had a cash balance of approximately $5.8 million [13]. Operational Achievements - The company has initiated an evaluation of the Hemopurifier's compatibility with a simplified blood treatment system, which could enhance treatment delivery in oncology units [11]. - Significant cost management efforts have led to reductions in payroll, general and administrative expenses, and professional fees [17].

Core Insights - Aethlon Medical has made significant progress in its Australian oncology trial, completing the first treatment cohort and amending the protocol to broaden patient eligibility [1][2][5] - The company reported a 31.6% reduction in operating expenses for the fiscal first quarter, enhancing operational efficiency [10][16] - Promising preclinical data supports the potential of the Hemopurifier in treating various conditions, including Long COVID [10][12][14] Clinical Progress - The first treatment cohort in the Australian trial involved patients with solid tumors unresponsive to PD-1 inhibitors, with no serious adverse events reported [3][4] - The independent Data Safety Monitoring Board recommended advancing to the second treatment cohort, which will involve two Hemopurifier treatments within a week [4] - The trial aims to assess safety and the potential to improve the body's natural ability to attack tumor cells by reducing extracellular vesicle concentrations [7][8] Financial Performance - As of June 30, 2025, Aethlon had a cash balance of approximately $3.8 million [15] - Consolidated operating expenses for the quarter were approximately $1.8 million, down from $2.6 million in the same period last year [16][20] - The operating loss for the quarter decreased to $1.8 million compared to $2.6 million for the same period in 2024 [20] Preclinical and Research Developments - Aethlon's preclinical study demonstrated a 98.5% removal of platelet-derived extracellular vesicles from healthy human plasma during a simulated 4-hour treatment [10][11] - The company is collaborating with UCSF to explore the Hemopurifier's potential applications in Long COVID, with initial findings presented at a recent symposium [12][13][14] Strategic Decisions - Aethlon decided not to proceed with a planned oncology trial in India due to extended timelines and costs, allowing the company to focus on its ongoing trial in Australia [9] - The amended protocol for the Australian trial reflects current standards of care, expanding eligibility to patients receiving various treatment regimens that include anti-PD-1 agents [5]